浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Mining and analysis of adverse drug reaction signals of melphalan based on FAERS
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1493-1497(2023)
- 作者机构：
1.安徽医科大学附属亳州医院静配中心，安徽 亳州 236800
2.安徽医科大学附属亳州医院药学部，安徽 亳州 236800
3.蚌埠医学院公共基础学院，安徽 蚌埠 233030
4.亳州学院中药学院，安徽 亳州 236800
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.12.16
CLC： R969.3;R979.1Published：30 June 2023，
Received：03 January 2023，
Revised：01 April 2023，
扫 描 看 全 文
狄潘潘,梁海,王杰等.基于FAERS的美法仑不良反应信号挖掘与分析 Δ[J].中国药房,2023,34(12):1493-1497.
DI Panpan,LIANG Hai,WANG Jie,et al.Mining and analysis of adverse drug reaction signals of melphalan based on FAERS[J].ZHONGGUO YAOFANG,2023,34(12):1493-1497.
狄潘潘,梁海,王杰等.基于FAERS的美法仑不良反应信号挖掘与分析 Δ[J].中国药房,2023,34(12):1493-1497. DOI： 10.6039/j.issn.1001-0408.2023.12.16.
DI Panpan,LIANG Hai,WANG Jie,et al.Mining and analysis of adverse drug reaction signals of melphalan based on FAERS[J].ZHONGGUO YAOFANG,2023,34(12):1493-1497. DOI： 10.6039/j.issn.1001-0408.2023.12.16.
摘要
目的
2
挖掘美法仑的不良反应（ADR）信号，为临床安全使用提供参考。
方法
2
利用OpenVigil 2.1数据平台，收集美国FDA不良事件报告系统（FAERS）数据库中2004年第1季度至2022年第2季度的美法仑相关ADR报告，利用比例失衡法中的报告比值比（ROR）法和综合标准法（MHRA）进行数据挖掘，根据《国际医学用语词典》（24.0版）ADR术语集中的系统器官分类（SOC）和首选术语（PT）对ADR报告进行描述和分类。
结果
2
共检索到目标药物美法仑相关ADR报告17 046份，ADR报告数呈波动上升趋势；ADR报告涉及患者以男性为主（43.28%），且集中于50～＜75岁（35.09%），主要上报国家为美国（23.97%）；共涉及严重结局22 842例次，以住院或延长住院为主（24.45%）。共挖掘到403个ADR信号，涉及23种SOC，主要为血液及淋巴系统疾病（801例次，13.77%），其次为眼器官疾病（755例次，12.97%）和感染及侵袭类疾病（716例次，12.30%）。报告例次排名靠前的ADR信号涉及发热性中性粒细胞减少、腹泻、发热及黏膜炎等PT，肺炎、脓毒症、玻璃体积血、脉络膜视网膜萎缩、骨髓增生异常综合征等PT未被药品说明书收录；信号强度排名靠前的ADR信号涉及脉络膜营养不良、脉络膜视网膜萎缩、眼球萎缩等PT，且上述3种PT均未被药品说明书收录。
结论
2
美法仑导致的ADR主要包括血液及淋巴系统疾病、眼器官疾病和感染及侵袭类疾病；使用美法仑前，临床应做好用药评估，并在治疗期间重点关注患者的血液指标和眼部毒性反应，以保障治疗的安全性。
Abstract
OBJECTIVE
2
To mine the adverse drug reaction （ADR） signals of melphalan， so as to provide reference for clinically safe drug use.
METHODS
2
Using OpenVigil 2.1 data platform， relative ADR reports of melphalan from the first quarter of 2004 to the second quarter of 2022 in FAERS database were collected； data mining was conducted using the reported odds ratio （ROR） method and Medicines and Healthcare Products Regulatory Agency （MHRA） method of disproportional method. ADR reports were described and classified according to the system organ class （SOC） and preferred term （PT） in
Medical Dictionary for Regulatory Activities
（24.0 edition）.
RESULTS
2
A total of 17 046 ADR reports related to the target drug melphalan were retrieved， and the number of ADR reports showed a fluctuating upward trend； the majority of patients were male （43.28%）， and were concentrated between the ages of 50-＜75 （35.09%）， with the main reporting country being the United States （23.97%）； ADR report involved a total of 22 842 severe outcomes， mainly including hospitalization or extended hospitalization （24.45%）. Totally 403 ADR signals were detected， involving 23 SOC， mainly including blood and lymphatic system diseases （801 cases， 13.77%）， followed by eye organ diseases （755 cases， 12.97%） and infectious and invasive diseases （716 cases， 12.30%）. The ADR signals ranked high in the number of reported cases included febrile neutropenia， diarrhea， fever and mucositis and other PT； PT such as pneumonia， sepsis， vitreous hemorrhage， chorioretinal atrophy， myelodysplastic syndrome were not recorded in drug instructions. The ADR signals with high signal strength ranking included choroidal dystrophy， chorioretinal atrophy， eyeball atrophy and other PT， and above three types of PT were not included in the drug instructions.
CONCLUSIONS
2
ADRs caused by melphalan mainly include blood and lymphatic system diseases， eye organ diseases， and infectious and invasive diseases； before using melphalan， it is necessary to evaluate the drug use of patients， and pay close attention to the patient’s blood indicators and eye toxicity reaction， so as to guarantee the safety of treatment.
关键词
美法仑美国FDA不良事件报告系统药物不良反应数据挖掘比值失衡法
Keywords
FAERS databaseadverse drug reactionsdata miningdisproportional method
references
MAURA F，WEINHOLD N，DIAMOND B，et al. The mutagenic impact of melphalan in multiple myeloma[J]. Leukemia，2021，35（8）：2145-2150.
HAMED R A，BAZARBACHI A H，MALARD F，et al. Current status of autologous stem cell transplantation for multiple myeloma[J]. Blood Cancer J，2019，9（4）：44.
TACCHETTI P，PANTANI L，PATRIARCA F，et al. Bor-tezomib，thalidomide，and dexamethasone followed by double autologous haematopoietic stem-cell transplan-tation for newly diagnosed multiple myeloma（GIMEMA-MMY-3006）：long-term follow-up analysis of a randomised phase 3，open-label study[J]. Lancet Haematol，2020，7（12）：e861-e873.
COLITA A，COLITA A，BUMBEA H，et al. LEAM vs. BEAM vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas： retrospec-tive comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant，on behalf of the Romanian Society for Bone Marrow Transplantation[J]. Front Oncol，2019，9：892.
VALDEZ B C，LI Y，MURRAY D，et al. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine，busulfan，and melphalan in multiple myeloma cells[J]. Exp Hematol，2020，81：32-41.
TAN T D，HONG Y C，LI S S，et al. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies：a prospective，observational study[J]. Chin J Physiol，2020，63（5）：211-217.
PAIVA B，PUIG N，CEDENA M T，et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma[J]. J Clin Oncol，2020，38（8）：784-792.
JOSEPH N S，KAUFMAN J L，DHODAPKAR M V，et al. Long-term follow-up results of lenalidomide，bortezomib，and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma[J]. J Clin Oncol，2020，38（17）：1928-1937.
ANTTILA J V，SHUBIN M，CAIRNS J，et al. Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression[J]. PLoS Comput Biol，2019，15（11）：e1007493.
明茜，余秋霞，张晓颖，等. 注射用盐酸美法仑在血液恶性肿瘤自体造血干细胞移植及其序贯嵌合抗原受体细胞治疗中的近期疗效及副作用[J]. 内科急危重症杂志，2022，28（1）：28-31，85.
KARATI D，MAHADIK K R，TRIVEDI P，et al. Alkyla-ting agents，the road less traversed，changing anticancer therapy[J]. Anticancer Agents Med Chem，2022，22（8）：1478-1495.
孔黛，王新凯，裴晓杭，等. 淋巴瘤自体造血干细胞移植中苯达莫司汀、依托泊苷、阿糖胞苷、美法仑（BeEAM）预处理方案的安全性[J]. 中国组织工程研究，2023，27（19）：2975-2979.
DIMOPOULOS M A，CAVO M，MATEOS M V，et al. A matching-adjusted indirect treatment comparison（MAIC）of daratumumab-bortezomib-melphalan-prednisone（D-VMP）versus lenalidomide-dexamethasone continuous（Rd continuous），lenalidomide-dexamethasone 18 months（Rd 18），and melphalan-prednisone-thalidomide（MPT）[J]. Leuk Lymphoma，2020，61（3）：714-720.
罗林，张佳颖，陈力，等. 基于美国FAERS数据库的托珠单抗不良事件信号挖掘[J]. 中国药房，2021，32（15）：1874-1879.
叶小飞. 上市后药品不良反应信号检测方法的进展与思考[J]. 海军军医大学学报，2022，43（2）：117-122.
HUANG J，CHAN S C，LOK V，et al. The epidemiological landscape of multiple myeloma：a global cancer regi-stry estimate of disease burden，risk factors，and temporal trends[J]. Lancet Haematol，2022，9（9）：e670-e677.
NADEEM O，ANDERSON K C. The safety of current and emerging therapies for multiple myeloma[J]. Expert Opin Drug Saf，2020，19（3）：269-279.
BOGAN C M，PIERCE J M，DOSS S D，et al. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds：efficacy，toxicity and stability in rabbits models and patients[J]. Exp Eye Res，2021，204：108439.
柴婷，任韩星，高丽. 经眼动脉灌注美法仑和卡铂治疗视网膜母细胞瘤的疗效观察[J]. 中国肿瘤临床与康复，2022，29（7）：867-870.
徐陆欣怡，王妮，尹适成，等. 我国罕见病药品的可及性及采购使用现状研究[J]. 中国卫生政策研究，2022，15（2）：60-64.
FABIAN I D，SAGOO M S. Understanding retinobla-stoma：epidemiology and genetics[J]. Community Eye Health，2018，31（101）：7.
YOUSEF Y A，AL JBOOR M，MOHAMMAD M，et al. Safety and efficacy of intravitreal chemotherapy（melphalan）to treat vitreous seeds in retinoblastoma[J]. Front Pharmacol，2021，12：696787.
XUE K，REN H，MENG F X，et al. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients[J]. BMC Ophthalmol，2019，19（1）：61.
BERRY J L，KIM M E，PEFKIANAKI M，et al. Intravi-treal melphalan for retinoblastoma：the impact of toxicity on recurrence and ultimate globe salvage[J]. Ocul Oncol Pathol，2020，6（6）：388-394.
YANG Y，XING Y Q，LIANG C Q，et al. In search of underlying mechanisms and potential drugs of melphalan-induced vascular toxicity through retinal endothelial cells using bioinformatics approach[J]. Tumour Biol，2016，37（5）：6709-6718.
HSIEH T，LIAO A，FRANCIS J H，et al. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma[J]. PLoS One，2020，15（7）：e0235016.
0
Views
8
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.